Vlad Vitoc has bought MAIA on 5 days since Aug 2022

Vlad Vitoc, MD, MBA, is a biopharmaceutical executive and the Chairman, Chief Executive Officer, and President of MAIA Biotechnology, Inc., a publicly traded clinical-stage cancer immunotherapy company focused on telomere-targeting agents.( As a corporate insider, he serves as CEO, director, and a 10% owner of MAIA Biotechnology and has recently increased his equity stake through open-market purchases of the company’s common stock.( He has more than 20 years of experience in commercial strategic analysis, planning, and medical affairs, having managed and supported over 20 compounds across early, launch, and mature stages, including targeted and immune therapies for more than 25 tumor types such as colorectal, hepatocellular, lung, breast, prostate, and renal cell cancers.(

Vitoc is also the founder and CEO of MAIA Biotechnology, which develops novel telomere-targeting and immunogenic small-molecule agents for multiple cancers, including non–small cell lung cancer and colorectal cancer.( His leadership at MAIA includes guiding the company’s oncology pipeline toward pivotal trial readiness and outlining key clinical and regulatory milestones to shareholders.( Vitoc earned his M.D. from the University of Medicine and Pharmacy “Iuliu Hațieganu” in Cluj-Napoca, Romania, and his M.B.A. from the University of South Carolina, combining medical training with business expertise in his executive role.(

Written by Perplexity from public sources.